We give an unconditional guarantee that if, according to the data of September, several EU member states take responsibility and finance the newly created drug for the treatment of achondroplasia from the state budget, Georgia will be one of the leading countries in the world that will share this responsibility and carry out the necessary procedures for the purchase of the drug, the Minister of Health, Zurab Azarashvili, said at a meeting with parents of patients diagnosed with achondroplasia. The information is disseminated by the Ministry of Health.
At the meeting, Zurab Azarashvili learned about the parents' needs and presented them with information obtained from international organizations regarding the drug "Vosoritide".
"At the meeting, it was noted that due to the existence of scarce data regarding the medicine, the developed countries of the world are careful about this issue in order to guarantee the patient's safety as much as possible. Therefore, at this stage, treatment with the mentioned drug is not financed from the state budget in any country of the world. The authorization of the medicine by the US Food and Drug Agency (FDA) and the European Medicines Agency (EMA) refers to the right to enter and sell the medicine in the countries and does not automatically mean the funding of the medicine from the budget.
It was noted that the decision to finance medicines from the state budget is not made unilaterally, and the issue is discussed by specialists, doctors and experts based on joint reconciliation.
Zurab Azarashvili, at the meeting with the patients' parents, once again confirmed the agency's readiness that the state will finance the diagnosis and treatment of children with other concomitant diseases both in Georgia and abroad.
Achondroplasia is a rare disease that is characterized by growth retardation in human height. People with this disease have a normal life expectancy, normal intelligence, despite the delay in growth," the information released by the Ministry reads.
